Tags

Type your tag names separated by a space and hit enter

A Prospective Study of Urinary Prostaglandin E2 Metabolite, Helicobacter pylori Antibodies, and Gastric Cancer Risk.
Clin Infect Dis. 2017 May 15; 64(10):1380-1386.CI

Abstract

Background

Previous studies suggest that a stable end-product of prostaglandin E2, the urinary metabolite PGE-M, is associated with colorectal cancer, and 1 study of relatively small sample size found an association with gastric cancer among women. In the present study we further investigate the PGE-M, Helicobacter pylori, and gastric cancer association.

Methods

The present analysis included 359 prospectively ascertained gastric cancer cases and 700 individually matched controls from the Shanghai Women's and Men's Health Studies. Urinary PGE-M was measured by a liquid chromatography/tandem mass spectrometric method. Seropositivity to 15 H. pylori recombinantly expressed fusion proteins was detected by H. pylori multiplex serology.

Results

Adjusting for H. pylori, increasing PGE-M was associated with higher risk of gastric cancer (quartile 4 vs 1: odds ratio [OR], 1.76 [95% confidence interval {CI}, 1.17-2.66], Ptrend = .004). This association remained after excluding those diagnosed within 2 years from sample collection (OR, 1.73 [95% CI, 1.12-2.65], Ptrend = .007). However it was no longer present among individuals with 10 or more years of follow-up (2-4.9 years: OR, 3.15 [95% CI, 1.11-8.91]; 5-9.9 years: OR, 2.23 [95% CI, 1.22-4.06]; ≥10 years: OR, 0.73 [95% CI, .31-1.70]). Compared to H. pylori-negative individuals with below-median PGE-M levels, H. pylori-positive individuals with above-median PGE-M levels had a 5-fold increase in the odds of gastric cancer (OR, 5.08 [95% CI, 2.47-10.43]).

Conclusions

In China, higher PGE-M levels may indicate an increased risk of gastric cancer independent of the risk conferred by H. pylori infection status, particularly for cancers diagnosed within 10 years of sample collection.

Authors+Show Affiliations

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Cancer Epidemiology, Peking University Cancer Hospital and Institute, Peking University Health Science Center, Beijing, China. Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center and Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center and Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center and Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.Division of Molecular Diagnostics of Oncogenic Infections, Research Program in Infection, Inflammation, and Cancer, German Cancer Research Center, Heidelberg, Germany.Division of Molecular Diagnostics of Oncogenic Infections, Research Program in Infection, Inflammation, and Cancer, German Cancer Research Center, Heidelberg, Germany.Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.Department of Epidemiology, Shanghai Cancer Institute, China; and.Department of Epidemiology, Shanghai Cancer Institute, China; and.Department of Epidemiology, Shanghai Cancer Institute, China; and.Division of Cancer Epidemiology and Genetics, Occupational and Environmental Epidemiology Branch, National Cancer Institute, National Institutes of Health, Rockville, Maryland.Division of Cancer Epidemiology and Genetics, Occupational and Environmental Epidemiology Branch, National Cancer Institute, National Institutes of Health, Rockville, Maryland.Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center and Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center and Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28402440

Citation

Wang, Tianyi, et al. "A Prospective Study of Urinary Prostaglandin E2 Metabolite, Helicobacter Pylori Antibodies, and Gastric Cancer Risk." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 64, no. 10, 2017, pp. 1380-1386.
Wang T, Cai H, Zheng W, et al. A Prospective Study of Urinary Prostaglandin E2 Metabolite, Helicobacter pylori Antibodies, and Gastric Cancer Risk. Clin Infect Dis. 2017;64(10):1380-1386.
Wang, T., Cai, H., Zheng, W., Michel, A., Pawlita, M., Milne, G., Xiang, Y. B., Gao, Y. T., Li, H. L., Rothman, N., Lan, Q., Shu, X. O., & Epplein, M. (2017). A Prospective Study of Urinary Prostaglandin E2 Metabolite, Helicobacter pylori Antibodies, and Gastric Cancer Risk. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 64(10), 1380-1386. https://doi.org/10.1093/cid/cix106
Wang T, et al. A Prospective Study of Urinary Prostaglandin E2 Metabolite, Helicobacter Pylori Antibodies, and Gastric Cancer Risk. Clin Infect Dis. 2017 May 15;64(10):1380-1386. PubMed PMID: 28402440.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A Prospective Study of Urinary Prostaglandin E2 Metabolite, Helicobacter pylori Antibodies, and Gastric Cancer Risk. AU - Wang,Tianyi, AU - Cai,Hui, AU - Zheng,Wei, AU - Michel,Angelika, AU - Pawlita,Michael, AU - Milne,Ginger, AU - Xiang,Yong-Bing, AU - Gao,Yu-Tang, AU - Li,Hong-Lan, AU - Rothman,Nathaniel, AU - Lan,Qing, AU - Shu,Xiao-Ou, AU - Epplein,Meira, PY - 2016/10/18/received PY - 2017/01/10/accepted PY - 2017/4/13/pubmed PY - 2018/1/24/medline PY - 2017/4/13/entrez KW - Helicobacter pylori KW - inflammation. KW - serology KW - stomach neoplasms SP - 1380 EP - 1386 JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JO - Clin. Infect. Dis. VL - 64 IS - 10 N2 - Background: Previous studies suggest that a stable end-product of prostaglandin E2, the urinary metabolite PGE-M, is associated with colorectal cancer, and 1 study of relatively small sample size found an association with gastric cancer among women. In the present study we further investigate the PGE-M, Helicobacter pylori, and gastric cancer association. Methods: The present analysis included 359 prospectively ascertained gastric cancer cases and 700 individually matched controls from the Shanghai Women's and Men's Health Studies. Urinary PGE-M was measured by a liquid chromatography/tandem mass spectrometric method. Seropositivity to 15 H. pylori recombinantly expressed fusion proteins was detected by H. pylori multiplex serology. Results: Adjusting for H. pylori, increasing PGE-M was associated with higher risk of gastric cancer (quartile 4 vs 1: odds ratio [OR], 1.76 [95% confidence interval {CI}, 1.17-2.66], Ptrend = .004). This association remained after excluding those diagnosed within 2 years from sample collection (OR, 1.73 [95% CI, 1.12-2.65], Ptrend = .007). However it was no longer present among individuals with 10 or more years of follow-up (2-4.9 years: OR, 3.15 [95% CI, 1.11-8.91]; 5-9.9 years: OR, 2.23 [95% CI, 1.22-4.06]; ≥10 years: OR, 0.73 [95% CI, .31-1.70]). Compared to H. pylori-negative individuals with below-median PGE-M levels, H. pylori-positive individuals with above-median PGE-M levels had a 5-fold increase in the odds of gastric cancer (OR, 5.08 [95% CI, 2.47-10.43]). Conclusions: In China, higher PGE-M levels may indicate an increased risk of gastric cancer independent of the risk conferred by H. pylori infection status, particularly for cancers diagnosed within 10 years of sample collection. SN - 1537-6591 UR - https://www.unboundmedicine.com/medline/citation/28402440/A_Prospective_Study_of_Urinary_Prostaglandin_E2_Metabolite_Helicobacter_pylori_Antibodies_and_Gastric_Cancer_Risk_ L2 - https://academic.oup.com/cid/article-lookup/doi/10.1093/cid/cix106 DB - PRIME DP - Unbound Medicine ER -